- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04292327
Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus (2019-nCoV)
Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus(2019-nCoV)
Objects: The purpose of this study was to observe the characteristics of morbidity, disease progression and therapeutic effects of 2019-novel coronavirus pneumonia patients with different clinical types.
Method: A single center, retrospective and observational study was used to collect COVID-19 patients admitted to Wuhan Infectious Diseases Hospital (Wuhan JinYinTan Hospital) from January 2020 to March 2020. The general information, first clinical symptoms, hospitalization days, laboratory examination, CT examination, antiviral drugs, immune enhancers, traditional Chinese medicine treatment and other clinical intervention measures were recorded, and the nutritional status and prognosis of the patients were recorded. confirm COVID-19 's disease progression, clinical characteristics, disease severity and treatment effects. To compare the characteristics of disease progression, clinical features, disease severity and therapeutic effect of different types of COVID-19.
Outcomes: The characteristics of disease progression, clinical features, disease severity and therapeutic effect of different types of COVID-19.
Conclusion: The characteristics of disease progression, clinical features and therapeutic effect of different types of COVID-19.
Visão geral do estudo
Status
Condições
Descrição detalhada
Since December 2019, patients with unexplained pneumonia have appeared in some medical institutions in Wuhan, China. Nucleic acid testing was completed on January 10, 2020, which was confirmed to be caused by 2019-novel coronavirus. In 2020, the World Health Organization(WHO) named the virus 2019-novel coronavirus(2019-nCoV). The WHO announced that the pneumonia caused by 2019-nCoV is officially called COVID-19. Today, more than 70,000 cases have been confirmed and more than 2,000 patients have died.
At present, the epidemiological characteristics, laboratory indicators, imaging features and clinical treatment effects of COVID-19 should be reported, but the sample size is small. Large sample studies are still needed to further confirm COVID-19 's disease progression, clinical characteristics, disease severity and treatment effects, so as to provide a scientific basis for future clinical treatment. Therefore, it is particularly important to further review the relationship between the characteristics and prognosis of such patients.
Tipo de estudo
Inscrição (Antecipado)
Contactos e Locais
Locais de estudo
-
-
Fujian
-
Fuzhou, Fujian, China, 350000
- Fujian Provincial Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion criteria.
- 2019-nCov (SARA-Cov-2) nucleic acid positive detected by PCR.
- Older than 18 years old and younger than 75 years old.
- Meet the diagnostic criteria of COVID-19 for different types (including ordinary type, heavy type and critical type)
Exclusion criteria.
- the age is less than 18 years old;
- pregnant or lactating women;
- severe underlying diseases, such as advanced malignant tumor, end-stage lung disease, etc.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: Outro
- Perspectivas de Tempo: Retrospectivo
Coortes e Intervenções
Grupo / Coorte |
---|
The ordinary COVID-19
Consistent with the diagnosis of ordinary COVID-19.
|
The heavy COVID-19.
Consistent with the diagnosis of heavy COVID-19.
|
The critical COVID-19
Consistent with the diagnosis of critical COVID-19
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Mortality
Prazo: 28 day
|
The mortality of COVID-19 in 28 days
|
28 day
|
The time interval of Nucleic acid detection become negative
Prazo: 28 day
|
The time interval of COVID-19 form nucleic acid confirmed to the nucleic acid detection turn into negative.
|
28 day
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Xiuling Shang, Fujian Provincial Hospital
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- KY-2020-24.01
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .